FKBPs (FK506-binding proteins) have long been recognized as key regulators of the response to immunosuppressant drugs and as co-chaperones of steroid receptor complexes. More recently, evidence has emerged suggesting that this diverse protein family may also represent cancer biomarkers owing to their roles in cancer progression and response to treatment. FKBPL (FKBP-like) is a novel FKBP with roles in GR (glucocorticoid receptor), AR (androgen receptor) and ER (oestrogen receptor) signalling. FKBPL binds Hsp90 (heat-shock protein 90) and modulates translocation, transcriptional activation and phosphorylation of these steroid receptors. It has been proposed as a novel prognostic and predictive biomarker, where high levels predict for increased recurrence-free survival in breast cancer patients and enhanced sensitivity to endocrine therapy. Since this protein family has roles in a plethora of signalling pathways, its members represent novel prognostic markers and therapeutic targets for cancer diagnosis and treatment.
Skip Nav Destination
Article navigation
April 2011
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
March 22 2011
The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL
Hayley D. McKeen;
Hayley D. McKeen
*School of Pharmacy, McClay Research Centre, Queen's University, Belfast, U.K.
Search for other works by this author on:
Donal J. Brennan;
Donal J. Brennan
†UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland
Search for other works by this author on:
Shauna Hegarty;
Shauna Hegarty
‡Whitla Medical Building, Queens University, Belfast, U.K.
Search for other works by this author on:
Fiona Lanigan;
Fiona Lanigan
†UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland
Search for other works by this author on:
Karin Jirstrom;
Karin Jirstrom
§Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Skåne University Hospital, Malmö, Sweden
Search for other works by this author on:
Christopher Byrne;
Christopher Byrne
*School of Pharmacy, McClay Research Centre, Queen's University, Belfast, U.K.
Search for other works by this author on:
Anita Yakkundi;
Anita Yakkundi
*School of Pharmacy, McClay Research Centre, Queen's University, Belfast, U.K.
Search for other works by this author on:
Helen O. McCarthy;
Helen O. McCarthy
*School of Pharmacy, McClay Research Centre, Queen's University, Belfast, U.K.
Search for other works by this author on:
William M. Gallagher;
William M. Gallagher
†UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland
Search for other works by this author on:
Tracy Robson
Tracy Robson
1
*School of Pharmacy, McClay Research Centre, Queen's University, Belfast, U.K.
1To whom correspondence should be addressed (email t.robson@qub.ac.uk).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
December 01 2010
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2011 Biochemical Society
2011
Biochem Soc Trans (2011) 39 (2): 663–668.
Article history
Received:
December 01 2010
Citation
Hayley D. McKeen, Donal J. Brennan, Shauna Hegarty, Fiona Lanigan, Karin Jirstrom, Christopher Byrne, Anita Yakkundi, Helen O. McCarthy, William M. Gallagher, Tracy Robson; The emerging role of FK506-binding proteins as cancer biomarkers: a focus on FKBPL. Biochem Soc Trans 1 April 2011; 39 (2): 663–668. doi: https://doi.org/10.1042/BST0390663
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.